Leerink Partners Reiterates Outperform Rating on Spyre (SYRE): 'today's update reflects SYRE's strong clinical execution'
Leerink Partners analyst Thomas J. Smith reiterated an Outperform rating and $49.00 price target on Spyre (NASDAQ: SYRE)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)